

In Vitro Methods
in Cell-Mediated
and Tumor Immunity

Edited by

BARRY R. BLOOM

JOHN R. DAVID

***In Vitro* Methods in Cell-Mediated and Tumor Immunity**

Edited by

BARRY R. BLOOM

Departments of Microbiology and Immunology
and of Cell Biology
Albert Einstein College of Medicine
Bronx, New York

and

JOHN R. DAVID

Department of Medicine
Harvard Medical School
Robert B. Brigham Hospital
Boston, Massachusetts

With the Editorial Assistance of
Roberta David and Lenore Grollman



ACADEMIC PRESS New York San Francisco London 1976
A Subsidiary of Harcourt Brace Jovanovich, Publishers

LIST OF CONTRIBUTORS

Numbers in parentheses indicate the pages on which the author's contributions begin. Affiliations listed are current.

- Anthony C. Allison** (395) Clinical Research Centre, Harrow, Middlesex, England
- L. C. Andersson** (309) Department of Immunology, Biomedical Center, Uppsala, Sweden
- Robert D. Arbeit** (143) Division of Infectious Disease, Department of Medicine, Beth Israel Hospital, Boston, Massachusetts
- Fritz H. Bach** (741) Immunobiology Research Center, Departments of Medical Genetics and Surgery, University of Wisconsin School of Medicine, Madison, Wisconsin
- Charles M. Balch** (105) Departments of Surgery and Microbiology, University of Alabama in Birmingham, The Medical Center, Birmingham, Alabama
- R. W. Baldwin** (541) Nottingham Cancer Research Campaign Laboratories, University of Nottingham, Nottingham, England
- Michael A. Bean** (27, 471) Virginia Mason Research Center, Seattle, Washington
- Gunnar Bendixen** (629) Laboratory of Clinical Immunology, Medical Department, Rigshospitalet University Hospital, Copenhagen, Denmark
- Celso Bianco** (407) The Rockefeller University, New York, New York
- R. M. Blaese** (359) National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- Barry R. Bloom** (3, 27, 319) Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York
- K. Theodor Brunner** (423, 737) Swiss Institute for Experimental Cancer Research, Epalinges-sur-Lausanne, Switzerland
- A. C. Campbell** (511) Nuffield Department of Clinical Medicine, The Radcliffe Infirmary, Oxford, England
- Grace B. Cannon** (607) Department of Immunology, Litton Bionetics Research Laboratory, Kensington, Maryland
- Jean-Charles Cerottini** (27, 423, 737) Swiss Institute for Experimental Cancer Research, Epalinges-sur-Lausanne, Switzerland
- Leonard Chess** (255) Division of Tumor Immunology, Sidney Farber Cancer Center, Harvard Medical School, Boston, Massachusetts
- Winthrop Hallowell Churchill** (417) Robert B. Brigham and Peter Bent Brigham Hospitals, Boston, Massachusetts

- Connie Clark** (83) Departments of Laboratory Medicine and Pathology, University of Minnesota School of Medicine, and Veterans Administration Hospital, Minneapolis, Minnesota
- Edward A. Clark** (437) Department of Microbiology and Immunology, University of California School of Medicine, Los Angeles, California
- Zanvil A. Cohn** (3, 333, 341) The Rockefeller University, New York, New York
- Robert J. Connor** (481, 607) Biometry Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- Max D. Cooper** (105) Department of Pediatrics, University of Alabama in Birmingham, The Medical Center, Birmingham, Alabama
- Joyce M. Cox** (363) Division of Hematology—Oncology, Children's Hospital Medical Center, Boston, Massachusetts
- Peter Curtis** (217) Imperial Cancer Research Fund, Tumour Immunology Unit, Department of Zoology, University College, London, England
- John R. David** (3, 27, 417) Department of Medicine, Harvard Medical School, Robert B. Brigham Hospital, Boston, Massachusetts
- Jack H. Dean** (607, 621) Department of Immunology, Litton Bionetics Research Laboratory, Kensington, Maryland
- J. W. dePierre** (353) Department of Biological Chemistry, Harvard Medical School, Boston, Massachusetts
- Howard B. Dickler** (143) Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- Frank J. Dixon** (555) Scripps Clinic and Research Foundation, La Jolla, California
- Paul J. Edelson** (333) The Rockefeller University, New York, New York
- Alfred G. Ehlenberger** (113) Department of Pathology, New York University Medical Center, New York, New York
- M. J. Embelton** (541) Cancer Research Campaign Laboratories, University of Nottingham, Nottingham, England
- Howard D. Engers** (423, 737) Swiss Institute for Experimental Cancer Research, Epalinges-sur-Lausanne, Switzerland
- Gregory P. Fischetti** (613) Department of Immunology, Litton Bionetics Research Laboratory, Kensington, Maryland
- Helle Fogh** (677) Sloan-Kettering Institute for Cancer Research, Donald S. Walker Laboratory, Rye, New York
- Jørgen Fogh** (677) Sloan-Kettering Institute for Cancer Research, Donald S. Walker Laboratory, Rye, New York
- A. Forsgren** (193) Department of Clinical Bacteriology, University of Lund, Malmö General Hospital, Malmö, Sweden
- Elwin E. Fraley** (451) Department of Urologic Surgery, University of Minnesota, School of Medicine, Minneapolis, Minnesota
- Michael M. Frank** (203) Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

- Stig S. Frøland** (137) Institute of Immunology and Rheumatology, Rikshospitalet University Hospital, Oslo, Norway
- D. G. L. Gale** (511) Nuffield Department of Clinical Medicine, The Radcliffe Infirmary, Oxford, England
- Sidney H. Golub** (731) Division of Oncology, Departments of Surgery and of Microbiology and Immunology, University of California School of Medicine, Los Angeles, California
- Maureen Goodenow** (677) Sloan-Kettering Institute for Cancer Research, Donald S. Walker Laboratory, Rye, New York
- S. Gordon** (341) Sir William Dunn School of Experimental Pathology, Oxford, England
- Melvyn F. Greaves** (3, 89, 217) Imperial Cancer Research Fund, Tumour Immunology Unit, Department of Zoology, University College, London, England
- Ira Green** (203) Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland
- J. U. Gutterman** (587) Department of Developmental Therapeutics, M. D. Anderson Hospital and Tumor Institute, The University of Texas System Cancer Center, Houston, Texas
- Thomas R. Hakala** (451) Department of Surgery, Division of Urological Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania
- W. J. Halliday** (547) Department of Microbiology, University of Queensland, Brisbane, Queensland, Australia
- Sten Hammarström** (497) Department of Immunology, Wenner-Gren Institute, University of Stockholm, Stockholm, Sweden
- P. Häyry** (309) Transplantation Laboratory, Fourth Department of Surgery, University of Helsinki, Helsinki, Finland
- Ingegerd Hellström** (533) Fred Hutchinson Cancer Research Center, Seattle, Washington
- Karl Erik Hellström** (533) Fred Hutchinson Cancer Research Center, Seattle, Washington
- Ulla Hellström** (497) Department of Immunology, Wenner-Gren Institute, University of Stockholm, Stockholm, Sweden
- Pierre A. Henkart** (143) Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- Christopher S. Henney** (429) Departments of Medicine and Microbiology, The Johns Hopkins University School of Medicine, and The Neill Memorial Research Laboratories of The Good Samaritan Hospital, Baltimore, Maryland
- Ronald B. Herberman** (27, 461, 481, 489, 607, 613, 621, 723) Laboratory of Immunodiagnosis, Division of Cancer Biology and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- E. M. Hersh** (587) Department of Developmental Therapeutics, M.D. Anderson Hospital and Tumor Institute, The University of Texas System Cancer Center, Houston, Texas
- Thomas Hoffman** (71) The Rockefeller University, New York, New York
- Howard T. Holden** (489, 723) Laboratory of Immunodiagnosis, Division of Cancer Biology and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

- C. Y. Hunter (587)** Department of Developmental Therapeutics, M.D. Anderson Hospital and Tumor Institute, The University of Texas System Cancer Center, Houston, Texas
- Elaine S. Jaffe (203)** Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- George Janossy (89, 217)** Imperial Cancer Research Fund, Tumour Immunology Unit, Department of Zoology, University College, London, England
- Larry F. Jerome (607)** Department of Immunology, Litton Bionetics Research Laboratory, Kensington, Maryland
- Mikael Jondal (3, 187, 241, 263)** Department of Tumor Biology, Karolinska Institutet, Stockholm, Sweden
- Anna Kadish (319)** Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York
- Manuel E. Kaplan (83)** Department of Medicine, University of Minnesota School of Medicine, Minneapolis, Minnesota
- Manfred L. Karnovsky (353)** Department of Biological Chemistry, Harvard Medical School, Boston, Massachusetts
- Mogens Kjaer (629)** Laboratory for Clinical Immunology, Medical Department, Rigshospitalet University Hospital, Copenhagen, Denmark
- Yoshihisa Kodera (471)** Virginia Mason Research Center, Seattle, Washington
- I. R. Koski (359)** National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- Henry G. Kunkel (3, 71)** The Rockefeller University, New York, New York
- S. Labaume (155)** Institut de Recherches sur les Maladies du Sang, Hôpital Saint-Louis, Paris, France
- Peter Lachmann (369)** Laboratory of Molecular Biology, The Medical School, Cambridge, England
- Paul-H. Lambert (565)** WHO Research and Training Centre, Hôpital Cantonal, Centre de Transfusion, Geneva, Switzerland
- Paul H. Lange (451)** Department of Surgery/Urology, Veterans Administration Hospital, and Department of Surgery, University of Minnesota School of Medicine, Minneapolis, Minnesota
- H. Sherwood Lawrence (27)** Department of Medicine, New York University Medical Center, New York, New York
- Alexander R. Lawton (105)** Department of Pediatrics, University of Alabama in Birmingham, The Medical Center, Birmingham, Alabama
- James Loveless (677)** Sloan-Kettering Institute for Cancer Research, Donald S. Walker Laboratory, Rye, New York
- Diane Lowe (369)** Laboratory of Molecular Biology, The Medical School, Cambridge, England
- James L. McCoy (607, 621)** Department of Developmental Therapeutics, M.D. Anderson Hospital and Tumor Institute, The University of Texas System Cancer Center, Houston, Texas
- Ian C. M. MacLennan (27, 511)** Nuffield Department of Clinical Medicine, The Radcliffe Infirmary, Oxford, England

- Adel A. F. Mahmoud** (387) Division of Geographic Medicine, Department of Medicine, Case Western Reserve University, and University Hospitals, Cleveland, Ohio
- Bruce A. Maurer** (613) Department of Immunology, Litton Bionetics Research Laboratory, Kensington, Maryland
- G. M. Mavligit** (587) Department of Developmental Therapeutics, M.D. Anderson Hospital and Tumor Institute, The University of Texas System Cancer Center, Houston, Texas
- Christopher Meade** (369) Clinical Research Centre, Harrow, Middlesex, England
- E. Merler** (279) Department of Pediatrics, Children's Hospital Medical Center, Boston, Massachusetts
- Richard G. Miller** (283) Department of Medical Biophysics, University of Toronto, and The Ontario Cancer Institute, Toronto, Ontario, Canada
- Robert D. Nelson** (663) Department of Pediatrics, University of Minnesota School of Medicine, Minneapolis, Minnesota
- Kenneth Nilsson** (713) The Wallenberg Laboratory, University of Uppsala, Uppsala, Sweden
- S. Nordling** (309) Third Department of Pathology and Fourth of Surgery, University of Helsinki, Helsinki, Finland
- Myrthel E. Nunn** (489) Laboratory of Immunodiagnosis, Division of Cancer Biology and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- Victor Nussenzweig** (3, 113) Department of Pathology, New York University Medical Center, New York, New York
- Robert K. Oldham** (461, 481, 723) Division of Oncology, Department of Medicine, Vanderbilt University Hospital, Nashville, Tennessee
- J. J. Oppenheim** (231, 573) Cellular Immunology Section, Laboratory of Microbiology and Immunology, National Institute of Dental Research, National Institutes of Health, Bethesda, Maryland
- John R. Ortaldo** (723) Laboratory of Immunodiagnosis, Division of Cancer Biology and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- Carol O'Toole** (437) Departments of Surgery/Urology and of Microbiology and Immunology, University of California School of Medicine, Los Angeles, California
- M. B. Pepys** (197) Department of Immunology, Royal Free Hospital School of Medicine, London, England
- Hedvig Perlmann** (497) Department of Immunology, Wenner-Gren Institute, University of Stockholm, Stockholm, Sweden
- Peter Perlmann** (27, 497, 523) Department of Immunology, Wenner-Gren Institute, University of Stockholm, Stockholm, Sweden
- Willy F. Piessens** (417) Department of Medicine, Harvard Medical School, Robert B. Brigham Hospital, Boston, Massachusetts
- Marilyn Pike** (651) Division of Rheumatic and Genetic Diseases, Departments of Medicine and of Microbiology and Immunology, Duke University Medical Center, Durham, North Carolina
- Margaret J. Polley** (123) Department of Medicine, New York Hospital-Cornell Medical Center, New York, New York

- D. G. Poplack** (359) National Cancer Institute, National Institutes of Health, Bethesda, Maryland
- Carl O. Povlsen** (701) Pathological-Anatomical Institute, Copenhagen Municipal Hospital, and Copenhagen County Hospital in Gentofte, Hellerup, Denmark
- J. L. Preud'homme** (155) Laboratoire de Immunochemie et Immunopathologie, Institut de Recherches sur les Maladies du Sang, Hôpital Saint-Louis, Paris, France
- Paul G. Quie** (663) Department of Pediatrics, University of Minnesota School of Medicine, Minneapolis, Minnesota
- Heinz G. Remold** (3) Department of Medicine, Harvard Medical School, Robert B. Brigham Hospital, Boston, Massachusetts
- R. A. Robins** (541) Nottingham Cancer Research Campaign Laboratories, University of Nottingham, Nottingham, England
- Fred S. Rosen** (405) Department of Pediatrics, Children's Hospital Medical Center, Boston, Massachusetts
- D. L. Rosenstreich** (231, 573) Cellular Immunology Section, Laboratory of Microbiology and Immunology, National Institute of Dental Research, National Institutes of Health, Bethesda, Maryland
- Gordon D. Ross** (123) Department of Medicine, New York Hospital-Cornell Medical Center, New York, New York
- Jørgen Rygaard** (701) Pathological-Anatomical Institute, Copenhagen County Hospital, and Copenhagen County Hospital in Gentofte, Hellerup, Denmark
- Stuart F. Schlossman** (3, 255) Division of Tumor Immunology, Sidney Farber Cancer Center, Harvard Medical School, Boston, Massachusetts
- Hiroshi Shiku** (471) Human Cancer Serology, Memorial Sloan-Kettering Cancer Center, New York, New York
- Ken Shortman** (267) Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
- Richard L. Simmons** (663) Department of Surgery, University of Minnesota School of Medicine, Minneapolis, Minnesota
- David F. Siwarski** (613) Department of Immunology, Litton Bionetics Research Laboratory, Kensington, Maryland
- Ralph Snyderman** (651) Division of Rheumatic and Genetics Diseases, Departments of Medicine and of Microbiology and Immunology, Duke University Medical Center, Durham, North Carolina
- Lynn E. Spitler** (645) Laboratory of Cellular Immunology, Children's Hospital Medical Center, and University of California Medical Center, San Francisco, California
- Ralph M. Steinman** (379) The Rockefeller University, New York, New York
- Jan Stjernswärd** (597) Ludwig Institute for Cancer Research (Lausanne Branch), Swiss Institute for Experimental Cancer Research, Lausanne, Switzerland
- Gerald Stoner** (319) Department of Microbiology and Immunology, Albert Einstein College of Medicine of Yeshiva University, Bronx, New York
- Thomas P. Stossel** (363) Medical Oncology Unit, Massachusetts General Hospital, Boston, Massachusetts

- Osias Stutman** (27) Department of Cellular Immunology, Memorial Sloan-Kettering Cancer Center, New York, New York
- Simon Sutcliffe** (319) Department of Medical Oncology, St. Bartholomew's Hospital, London, England
- A. Svedjelund** (193) Department of Immunology, Uppsala University Biomedical Center, Uppsala, Sweden
- Argyrios N. Theofilopoulos** (555) Department of Immunopathology, Scripps Clinic and Research Foundation, La Jolla, California
- Farkas Ványi** (597) Department of Tumor Biology, Karolinska Institutet, Stockholm, Sweden
- Christine Von Muller** (645) Laboratory of Cellular Immunology, Children's Hospital Medical Center, and University of California Medical Center, San Francisco, California
- S. M. Wahl** (231) Laboratory of Microbiology and Immunology, National Institute of Dental Research, National Institutes of Health, Bethesda, Maryland
- Birgitta Wåhlin** (523) Department of Immunology, Wenner-Gren Institute, University of Stockholm, Stockholm, Sweden
- Z. Werb** (341) Laboratory of Radiobiology, University of California School of Medicine, San Francisco, California
- Hans Wigzell** (3, 193, 245) Department of Immunology, Uppsala University Biomedical Center, Uppsala, Sweden
- Robert J. Winchester** (3, 171) The Rockefeller University, New York, New York
- Finn Wisløff** (137) Institute of Immunology and Rheumatology, Rikshospitalet University Hospital, Oslo, Norway
- Mildred Woodson** (83) Department of Hematology, Veterans Administration Hospital, Minneapolis, Minnesota
- Joyce M. Zarling** (741) Immunobiology Research Center, Departments of Medical Genetics and Surgery, University of Wisconsin School of Medicine, Madison, Wisconsin
- Rudolf H. Zubler** (565) WHO Research and Training Centre, Hôpital Cantonal, Centre de Transfusion, Geneva, Switzerland

PREFACE

The cell-mediated immune response is known to be crucially involved in such diverse phenomena as resistance to intracellular parasites (including viral, bacterial, fungal, and protozoal infection), contact allergy, rejection of transplanted organs and tissues, autoimmune disorders, and rejection of tumors. In the five years that have elapsed since the publication of the first volume of "*In Vitro Methods in Cell-Mediated Immunity*" there has been an explosion of interest and knowledge in the field of cell-mediated immunity. *In vitro* methods have been vital at two levels: first, in providing appropriate models and tools for understanding the basic mechanisms which underlie the response *in vivo*; and second, at the clinical level, in establishing useful indices of the actual and potential immune responsiveness of patients. Many of the methods appearing in the first volume had been developed only for animal models and have now been adapted and refined for application to human systems. Many novel techniques, which would not have been dreamed of five years ago, have been introduced for characterizing, separating, and assaying functions of the cell populations involved in cell-mediated immunity.

As is the case in all fields of science, our understanding of cell-mediated immunity can proceed no further than the methods by which it is studied will permit. It is the purpose of this book to make available, as widely as possible, much of the recently developed methodology in cell-mediated immunity so that it may be applied to diverse problems of fundamental and clinical importance. The book should serve both as a guide to investigators who will rely on the methods presented and as a stimulus for development of better methods and wider application of available methods to human disease.

The scope of this volume reflects the tremendous progress made, particularly in two broad areas. The first encompasses the characterization and enrichment of lymphocyte and macrophage populations, the basic cell types mediating the cell-mediated immune response. The second is tumor immunology, which we believe to hold enormous potential clinical importance for vast numbers of people. Because of the complexities and subtleties associated with the various methods and their applications, two expert panels were convened, with the support of the National Cancer Institute, to review critically the "state of the art" in each of the major areas and to evaluate the strengths, limitations, and

applications of the methods. Their contribution has been invaluable in providing a thoughtful and balanced perspective of the field.

We have indeed been privileged to have had such generous cooperation of the many scientists who have recorded their methods in detail for others to use. Because it was simply not feasible to include chapters from all of the many laboratories which have made significant contributions to methods in the field, we have had to select representative methods in a variety of areas, with the realization that those from other outstanding laboratories regrettably could not be included.

We wish to express our deep appreciation to the many people on whom this book depended. We thank Ms. Theodora Polihrom, Ms. Grace Sylvestri, and Ms. Karen Lahey for outstanding secretarial assistance. The expertise of the staff of Academic Press has been invaluable. We gratefully acknowledge the encouragement and advice of Dr. William Terry, the valuable assistance of Mr. William Fitzsimmons, and the support of the National Cancer Institute. We are indebted to Dr. Zanvil Cohn and The Rockefeller University for generously making available their outstanding facilities to the members of the expert panels. And, finally, we wish to express our sincere gratitude to all those contributors and expert panel members who generously agreed to give their valuable time and share their special knowledge with all who read this book.

Barry R. Bloom

John R. David

Contents of
IN VITRO METHODS IN CELL-MEDIATED IMMUNITY
Edited by Barry R. Bloom and Philip R. Glade

*Based on a Conference held May 28-29, 1970
at New York University-Bellevue Medical Center,
New York, New York*

Sessions

- I Methods for Study of Mediators
Chairman: Barry R. Bloom
- II Factors and Activities Produced *in Vitro* by Lymphocytes
Chairman: H. Sherwood Lawrence
- III Biological Implications of *in Vitro* Phenomena
Chairman: Kurt Hirschhorn
- IV Requirements and Prospects for Improved Methodology
Chairman: Maurice Landy

Methods

Index of Assays and Species

The Assay of Inhibition of Macrophage Migration and the Production of Migration Inhibitory Factor (MIF) and Skin Reactive Factor (SRF) in the Guinea Pig
Barry R. Bloom and Boyce Bennett

Assay for Inhibition of Macrophage Migration
John R. David and Roberta David

The "Migration-on-Agar" Technique for Measurement of Lymphocyte-Macrophage Interactions Associated with Delayed Hypersensitivity
Samuel B. Salvin and Jane Nishio

***In Vitro* Technique of the Cell Migration from the Spleen and/or Artificial Fragments**
Jan Švejcar, Jiri Johanovský, and Jan Pěkárek

The Capillary Tube Migration Inhibition Technique Applied to Human Peripheral Lymphocytes Using the Guinea Pig Peritoneal Exudate as the Indicator Cell Population
Daniel E. Thor

Method for the Production of MIF by Human Blood Lymphocytes
Ross E. Rocklin and John R. David

The Leucocyte Migration Technique for *in Vitro* Detection of Cellular Hypersensitivity in Man
Mogens Sjøborg

***In Vitro* Assay for Inhibition of Migration of Human Blood Leucocytes**
Steven A. Rosenberg and John R. David

The Capillary Technique for Measurement of Inhibition of Leucocyte Migration: An Assessment of Cell-Mediated Immunity
Rudolf E. Falk and John B. Zabriskie

The Use of Cultured Lymphocytic Cells as Target Cells for the Detection of Migration Inhibitory Factor
Philip R. Glade, Susan Westerman Broder, Harold Grotzky, and Kurt Hirschhorn

An *in Vitro* Test for Delayed Hypersensitivity: Macrophage Spreading Inhibition (M.S.I.)
Robert M. Fauve and Dragan Dekaris

The Technique for Observation of Migration and Aggregation of Human Blood Macrophages
Barbro Nordqvist and Hans Rorsman

The *in Vitro* Macrophage Aggregation Assay for Delayed Hypersensitivity
Samuel P. Gotoff, Somsak Lolekha, and Sheldon Dray

Lymphocyte Activation and Lymphotoxin Production*William P. Kolb, Terry W. Williams, and Gale A. Granger***Determination of Lymphocyte-Mediated Cytotoxicity by Release of Radioactivity from ^{14}C -Thymidine Labelled Cells***Göran Holm and Peter Perlmann***A Simplified Assay for the Cytotoxic Activity (Lymphotoxin) of Lymphocyte Culture Supernatants***Barry R. Bloom, Luis Jimenez, Linda Stein, and Lawrence Chessin* **^{51}Cr -Release from Chicken Erythrocytes: An Assay System for Measuring the Cytotoxic Activity of "Nonspecifically" Activated Lymphocytes *in Vitro****Peter Perlmann and Hedvig Perlmann****In Vitro* Assay of Target Cell Lysis by Sensitized Lymphocytes***Jean-Charles Cerottini and K. Theodore Brunner***The Technique of Clonal Inhibition: A Quantitative Assay for Human Lymphotoxin Activity***Arthur S. Lebowitz and H. Sherwood Lawrence***Production and Assay of a Lymphocyte Derived "Proliferation Inhibitory Factor" (PIF)***Sidney R. Cooperband and Jon A. Green***Coulter Counter Evaluation of the Death of Fibroblasts Mediated by Sensitized Lymphocytes in the Presence of Specific Antigen***Nancy H. Ruddle***Colony Inhibition and Cytotoxicity Assays***Ingegerd Hellström and Karl Erik Hellström***The Methodology of Microassay for Cell-Mediated Immunity (MCI)***M. Takasugi and Eva Klein*

The Demonstration of Lymphocyte Mitogenic Factor in the Guinea Pig*Robin A. Wolstencroft and Dudley C. Dumonde***Preparation and Assay of Mouse Mitogenic Factors***William H. Adler, Tomoo Takiguchi, and Richard T. Smith***The Preparation of a Lymphocyte Transforming Factor from Sensitive Lymphocytes Stimulated by Antigen***Fred Valentine***Lymphocyte Transformation: The Proliferation of Human Blood Lymphocytes Stimulated by Antigen *in Vitro****Fred Valentine***An Assay of Lymphocyte Blastogenesis Based on Measurement of the Rate of Protein Synthesis***William I. Waite and Kurt Hirschhorn***Leucocyte Culture Methodology: Production and Assay of Soluble Factors***Robert J. Hartzman and Fritz H. Bach***Preparation and Assay of an Inhibitor of DNA Synthesis and a Nonspecific Mitogen Elaborated by Human Lymphoblasts***Judith A. C. Bausher, William H. Adler, and Richard T. Smith***Assays for Chemotactic Factors***Peter A. Ward***A Plaque Inhibition Assay for Human Interferon Employing Human Neonate Skin Fibroblast Monolayers and Bovine Vesicular Stomatitis Virus***Thomas C. Merigan***Production and Assay of Human Lymphocyte Interferon Induced by Antigens***Jon A. Green and Sidney R. Cooperband*

***In Vitro* Production and Assessment of Activity of Skin Reactive Factors Released by Lymphoid Cells and Associated with Cellular Immunity**

Edgar Pick, Jan Krejci, and John L. Turk

The Preparation and Purification of Transfer Factor

H. Sherwood Lawrence and Salah Al-Askari

Conversion of Nonsensitive Lymph Node Cell Populations to Sensitive Cells with an RNA-Extract

Daniel E. Thor

Virus Plaque Assay for Antigen-Sensitive Cells in Delayed Hypersensitivity

Luis Jimenez and Barry R. Bloom

Preparation and Care of Established Human Lymphoid Cell Lines

Philip R. Glade and Susan Westerman Broder

Appendix Tables

Abbreviations

Index of Participants

CONTENTS

List of Contributors	xv
Preface	xxiii
Contents of " <i>In Vitro</i> Methods in Cell-Mediated Immunity," edited by Barry R. Bloom and Philip R. Glade	xxv

Section A / Evaluations

I	Evaluation of <i>in Vitro</i> Methods for Characterization of Lymphocytes and Macrophages	3
	<i>Barry R. Bloom, Zanvil A. Cohn, John R. David, Melvyn F. Greaves, Mikael Jondal, Henry G. Kunkel, Victor Nussenzweig, Heinz G. Remold, Stuart F. Schlossman, Hans Wigzell, and Robert J. Winchester</i>	
II	Evaluation of <i>in Vitro</i> Methods for Assaying Tumor Immunity	27
	<i>Michael A. Bean, Barry R. Bloom, Jean-Charles Cerottini, John R. David, Ronald B. Herberman, H. Sherwood Lawrence, Ian C. M. MacLennan, Peter Perlmann, and Osias Stutman</i>	

Section B / Methods

I. METHODS FOR CHARACTERIZATION OF LYMPHOCYTES AND MACROPHAGES

A. LYMPHOCYTES AND SURFACE MARKERS

T Cells

1	The E Rosette Test	71
	<i>Thomas Hoffman and Henry G. Kunkel</i>	
2	Detection of Human T Lymphocytes by Rosette Formation with AET-Treated Sheep Red Cells	83
	<i>Manuel E. Kaplan, Mildred Woodson, and Connie Clark</i>	
3	Antisera to Human T Lymphocytes	89
	<i>Melvyn F. Greaves and George Janossy</i>	